PRL
Dead / Abandoned — Abandoned — no statement of use filed (as of 29 Sept 2025)
What this means for you
This application is over — abandoned 29 Sept 2025. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 98214461
- Mark type
- Stylized text
- Filed
- 09 Oct 2023
- Published for opposition
- 31 Dec 2024
- Abandoned
- 29 Sept 2025
- Attorney of record
- Jonathan M. Gelchinsky
Goods and services
- Class 001 — Chemicals: Chemical and biological agents for scientific and research use, namely, lipids, lipid nanoparticles, lipid formulations, nucleic acids and modified nucleic acids, namely, short RNAs and messenger RNAs; nucleic acid sequences for scientific purposes, research purposes, and laboratory purposes other than medical and veterinary purposes
- Class 005 — Pharmaceuticals: Lipids, lipid nanoparticles, lipid formulations, nucleic acid molecules, enzymes, polypeptides, and small molecule compounds for medical use; pharmaceutical preparations and therapeutic agents, namely, for RNA, gene therapy and mRNA regulation; pharmaceutical and biological preparations for medical use for the treatment of genetic and genomic disorders by gene therapy and mRNA regulation for use in human and animal therapeutics; pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the prevention and treatment of genomic disorders in humans and animals; pharmaceutical preparations for gene therapy and mRNA regulation
- Class 042 — Scientific and technological services: Research and development in the field of technology and engineering of lipids, lipid nanoparticles, lipid formulations and RNAs for use in gene therapy and mRNA regulation; development of new technology for others for enabling the engineering and modification of lipids, lipid nanoparticles, lipid formulations, RNAs, namely, developing molecular and cellular biology reagents, techniques, and assays for use in pharmaceutical and biomedical industry
Owner
- ReNAgade Therapeutics Management, Inc., Watertown, MA, US
- ReNAgade Therapeutics Management, Inc., Watertown, MA, US
Prosecution history
- 29 Sept 2025 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 29 Sept 2025 — ABANDONMENT - NO USE STATEMENT FILED
- 25 Feb 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 31 Dec 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 31 Dec 2024 — PUBLISHED FOR OPPOSITION
- 25 Dec 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 04 Dec 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 01 Nov 2024 — ASSIGNED TO EXAMINER
- 30 Oct 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 30 Oct 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 30 Oct 2024 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 04 Oct 2024 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 04 Oct 2024 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 04 Oct 2024 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 04 Oct 2024 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED